Research Progress of Autologous Peripheral Blood Mononuclear Cell in the Treatment of Unexplained Recurrent Implantation Failure

doi:10.12280/gjszjk.20230176

Abstract

Abstract:

Recurrent implantation failure (RIF) brings huge economic and psychological burden to infertile couples. After excluding the known maternal-fetal factors, the incidence of unexplained RIF is still high. It is believed that immune factor is one of the potential causes. The success of embryo implantation depends on the local immune tolerance of the mother. Peripheral blood mononuclear cell (PBMC) contain T lymphocytes, B lymphocytes and monocytes. Intrauterine infusion of autologous PBMC can restore the immune balance and improve the endometrial receptivity and the implantation rate. Nowdays, the therapy with autologous PBMC intrauterine infusion has made some progress as a new potential treatment for unexplained RIF. However, the mechanism of therapeutic action is not yet clear, even the therapeutic effect is controversial. In addition, the culture method of PBMC, the number of intrauterine infusion cells, the timing of infusion and the applicable population still need to be further explored.

Key words: Recurrent implantation failure, Embryo transfer, Peripheral blood mononuclear cell, Immunotherapy, Administration, topical, Immune tolerance, Pregnancy outcome

LI Ning, ZHANG An-ni, ZHANG Xue-hong. Research Progress of Autologous Peripheral Blood Mononuclear Cell in the Treatment of Unexplained Recurrent Implantation Failure[J]. Journal of International Reproductive Health/Family Planning, 2023, 42(5): 403-408.

References 39

[1]	Sheikhansari G, Pourmoghadam Z, Danaii S, et al. Etiology and management of recurrent implantation failure: A focus on intra-uterine PBMC-therapy for RIF[J]. J Reprod Immunol, 2020, 139:103121. doi: 10.1016/j.jri.2020.103121. doi: 10.1016/j.jri.2020.103121 URL
[2]	Garneau AS, Young SL. Defining recurrent implantation failure: a profusion of confusion or simply an illusion?[J]. Fertil Steril, 2021, 116(6):1432-1435. doi: 10.1016/j.fertnstert.2021.10.023. doi: 10.1016/j.fertnstert.2021.10.023 pmid: 34836579
[3]	Wang Q, Sun Y, Fan R, et al. Role of inflammatory factors in the etiology and treatment of recurrent implantation failure[J]. Reprod Biol, 2022, 22(4):100698. doi: 10.1016/j.repbio.2022.100698. doi: 10.1016/j.repbio.2022.100698 URL
[4]	Wang W, Sung N, Gilman-Sachs A, et al. T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells[J]. Front Immunol, 2020, 11:2025. doi: 10.3389/fimmu.2020.02025. doi: 10.3389/fimmu.2020.02025 pmid: 32973809
[5]	Qin Q, Chang H, Zhou S, et al. Intrauterine administration of peripheral blood mononuclear cells activated by human chorionic gonadotropin in patients with repeated implantation failure: A meta-analysis[J]. J Reprod Immunol, 2021, 145:103323. doi: 10.1016/j.jri.2021.103323. doi: 10.1016/j.jri.2021.103323 URL
[6]	Yakin K, Oktem O, Urman B. Intrauterine administration of peripheral mononuclear cells in recurrent implantation failure: a systematic review and meta-analysis[J]. Sci Rep, 2019, 9(1):3897. doi: 10.1038/s41598-019-40521-w. doi: 10.1038/s41598-019-40521-w pmid: 30846784
[7]	Benkhalifa M, Joao F, Duval C, et al. Endometrium Immunomodulation to Prevent Recurrent Implantation Failure in Assisted Reproductive Technology[J]. Int J Mol Sci, 2022, 23(21):12787. doi: 10.3390/ijms232112787. doi: 10.3390/ijms232112787 URL
[8]	Franasiak JM, Alecsandru D, Forman EJ, et al. A review of the pathophysiology of recurrent implantation failure[J]. Fertil Steril, 2021, 116(6):1436-1448. doi: 10.1016/j.fertnstert.2021.09.014. doi: 10.1016/j.fertnstert.2021.09.014 pmid: 34674825
[9]	Alecsandru D, Klimczak AM, Garcia Velasco JA, et al. Immunologic causes and thrombophilia in recurrent pregnancy loss[J]. Fertil Steril, 2021, 115(3):561-566. doi: 10.1016/j.fertnstert.2021.01.017. doi: 10.1016/j.fertnstert.2021.01.017 pmid: 33610320
[10]	Turocy J, Williams Z. Novel therapeutic options for treatment of recurrent implantation failure[J]. Fertil Steril, 2021, 116(6):1449-1454. doi: 10.1016/j.fertnstert.2021.10.025. doi: 10.1016/j.fertnstert.2021.10.025 pmid: 34836580
[11]	Yu N, Zhang B, Xu M, et al. Intrauterine administration of autologous peripheral blood mononuclear cells (PBMCs) activated by HCG improves the implantation and pregnancy rates in patients with repeated implantation failure: a prospective randomized study[J]. Am J Reprod Immunol, 2016, 76(3):212-216. doi: 10.1111/aji.12542. doi: 10.1111/aji.12542 URL
[12]	Kong X, Tang G, Liu Y, et al. Efficacy of intrauterine infusion therapy before embryo transfer in recurrent implantation failure: A systematic review and network meta-analysis[J]. J Reprod Immunol, 2023, 156:103819. doi: 10.1016/j.jri.2023.103819. doi: 10.1016/j.jri.2023.103819 URL
[13]	Lessey BA. Assessment of endometrial receptivity[J]. Fertil Steril, 2011, 96(3):522-529. doi: 10.1016/j.fertnstert.2011.07.1095. doi: 10.1016/j.fertnstert.2011.07.1095 pmid: 21880273
[14]	Ahn JY, Hong YH, Kim KC, et al. Effect of Human Peripheral Blood Mononuclear Cells on Mouse Endometrial Cell Proliferation: A Potential Therapeutics for Endometrial Regeneration[J]. Gynecol Obstet Invest, 2022, 87(2):105-115. doi: 10.1159/000524232. doi: 10.1159/000524232 URL
[15]	Dimitriadis E, Menkhorst E, Saito S, et al. Recurrent pregnancy loss[J]. Nat Rev Dis Primers, 2020, 6(1):98. doi: 10.1038/s41572-020-00228-z. doi: 10.1038/s41572-020-00228-z pmid: 33303732
[16]	Wu Y, Li L, Liu L, et al. Autologous peripheral blood mononuclear cells intrauterine instillation to improve pregnancy outcomes after recurrent implantation failure: a systematic review and meta-analysis[J]. Arch Gynecol Obstet, 2019, 300(5):1445-1459. doi: 10.1007/s00404-019-05275-w. doi: 10.1007/s00404-019-05275-w pmid: 31631247
[17]	Rezaee D, Bandehpour M, Kazemi B, et al. Role of intrauterine administration of transfected peripheral blood mononuclear cells by GM-CSF on embryo implantation and pregnancy rate in mice[J]. Mol Hum Reprod, 2020, 26(2):101-110. doi: 10.1093/molehr/gaz068. doi: 10.1093/molehr/gaz068 pmid: 31899496
[18]	Benkhalifa M, Zayani Y, Bach V, et al. Does the dysregulation of matrix metalloproteinases contribute to recurrent implantation failure?[J]. Expert Rev Proteomics, 2018, 15(4):311-323. doi: 10.1080/14789450.2018.1464915. doi: 10.1080/14789450.2018.1464915 URL
[19]	Brownbill P, McKeeman GC, Brockelsby JC, et al. Vasoactive and permeability effects of vascular endothelial growth factor-165 in the term in vitro dually perfused human placental lobule[J]. Endocrinology, 2007, 148(10):4734-4744. doi: 10.1210/en.2007-0180. doi: 10.1210/en.2007-0180 pmid: 17640983
[20]	Su MT, Tsai PY, Tsai HL, et al. miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9[J]. Biofactors, 2017, 43(2):210-219. doi: 10.1002/biof.1325. doi: 10.1002/biof.1325 URL
[21]	Hashii K, Fujiwara H, Yoshioka S, et al. Peripheral blood mononuclear cells stimulate progesterone production by luteal cells derived from pregnant and non-pregnant women: possible involvement of interleukin-4 and interleukin-10 in corpus luteum function and differentiation[J]. Hum Reprod, 1998, 13(10):2738-2744. doi: 10.1093/humrep/13.10.2738. doi: 10.1093/humrep/13.10.2738 URL
[22]	Yoshioka S, Fujiwara H, Nakayama T, et al. Intrauterine administration of autologous peripheral blood mononuclear cells promotes implantation rates in patients with repeated failure of IVF-embryo transfer[J]. Hum Reprod, 2006, 21(12):3290-3294. doi: 10.1093/humrep/del312. doi: 10.1093/humrep/del312 pmid: 17021188
[23]	Rezaee D, Bandehpour M, Kazemi B, et al. Effects of human chorionic gonadotropin-producing peripheral blood mononuclear cells on the endometrial receptivity and implantation sites of the mouse uterus[J]. Clin Exp Reprod Med, 2022, 49(4):248-258. doi: 10.5653/cerm.2022.05358. doi: 10.5653/cerm.2022.05358 pmid: 36482499
[24]	Yu N, Yang J, Guo Y, et al. Intrauterine administration of peripheral blood mononuclear cells (PBMCs) improves endometrial receptivity in mice with embryonic implantation dysfunction[J]. Am J Reprod Immunol, 2014, 71(1):24-33. doi: 10.1111/aji.12150. doi: 10.1111/aji.12150 URL
[25]	Makrigiannakis A, BenKhalifa M, Vrekoussis T, et al. Repeated implantation failure: a new potential treatment option[J]. Eur J Clin Invest, 2015, 45(4):380-384. doi: 10.1111/eci.12417. doi: 10.1111/eci.12417 pmid: 25652716
[26]	Makrigiannakis A, Vrekoussis T, Makrygiannakis F, et al. Intrauterine CRH-treated PBMC in repeated implantation failure[J]. Eur J Clin Invest, 2019, 49(5):e13084. doi: 10.1111/eci.13084. doi: 10.1111/eci.13084 URL
[27]	Caruso A, Gaetano A, Scaccianoce S. Corticotropin-Releasing Hormone: Biology and Therapeutic Opportunities[J]. Biology(Basel), 2022, 11(12):1785. doi: 10.3390/biology11121785. doi: 10.3390/biology11121785
[28]	Zhang D, Yu Y, Duan T, et al. The role of macrophages in reproductive-related diseases[J]. Heliyon, 2022, 8(11):e11686. doi: 10.1016/j.heliyon.2022.e11686. doi: 10.1016/j.heliyon.2022.e11686 URL
[29]	Madkour A, Bouamoud N, Louanjli N, et al. Intrauterine insemination of cultured peripheral blood mononuclear cells prior to embryo transfer improves clinical outcome for patients with repeated implantation failures[J]. Zygote, 2016, 24(1):58-69. doi: 10.1017/S0967199414000719. doi: 10.1017/S0967199414000719 pmid: 25613318
[30]	Jin XH, Li Y, Li D. Intrauterine interventions for women with two or more implantation failures: A systematic review and network meta-analysis[J]. Front Endocrinol(Lausanne), 2022, 13:959121. doi: 10.3389/fendo.2022.959121. doi: 10.3389/fendo.2022.959121
[31]	Mei J, Yan Y, Jiang R, et al. Clinical outcome of intrauterine administration of peripheral mononuclear cells or human chorionic gonadotropin in unexplained implantation failure[J]. Am J Reprod Immunol, 2022, 87(5):e13529. doi: 10.1111/aji.13529. doi: 10.1111/aji.13529 URL
[32]	Holt-Kentwell A, Ghosh J, Devall A, et al. Evaluating interventions and adjuncts to optimize pregnancy outcomes in subfertile women: an overview review[J]. Hum Reprod Update, 2022, 28(4):583-600. doi: 10.1093/humupd/dmac001. doi: 10.1093/humupd/dmac001 pmid: 35137098
[33]	Fan Y, Lee R, Ng XW, et al. Subtle changes in perivascular endometrial mesenchymal stem cells after local endometrial injury in recurrent implantation failure[J]. Sci Rep, 2023, 13(1):225. doi: 10.1038/s41598-023-27388-8. doi: 10.1038/s41598-023-27388-8 pmid: 36604485
[34]	Vitagliano A, Di Spiezio Sardo A, Saccone G, et al. Endometrial scratch injury for women with one or more previous failed embryo transfers: a systematic review and meta-analysis of randomized controlled trials[J]. Fertil Steril, 2018, 110(4):687-702.e2. doi: 10.1016/j.fertnstert.2018.04.040. doi: S0015-0282(18)30394-7 pmid: 30196966
[35]	van Hoogenhuijze NE, Mol F, Laven J, et al. Endometrial scratching in women with one failed IVF/ICSI cycle-outcomes of a randomised controlled trial (SCRaTCH)[J]. Hum Reprod, 2021, 36(1):87-98. doi: 10.1093/humrep/deaa268. doi: 10.1093/humrep/deaa268
[36]	Lensen SF, Armstrong S, Gibreel A, et al. Endometrial injury in women undergoing in vitro fertilisation (IVF)[J]. Cochrane Database Syst Rev, 2021, 6(6):CD009517. doi: 10.1002/14651858.CD009517.pub4. doi: 10.1002/14651858.CD009517.pub4
[37]	Patrone D, Alessio N, Antonucci N, et al. Optimization of Peripheral Blood Mononuclear Cell Extraction from Small Volume of Blood Samples: Potential Implications for Children-Related Diseases[J]. Methods Protoc, 2022, 5(2):20. doi: 10.3390/mps5020020. doi: 10.3390/mps5020020 URL
[38]	Joao F, Ricaud G, Lamoureux J, et al. Intrauterine Administration of Activated Peripheral Blood Mononuclear Cells in Intrauterine Insemination: A Prospective Double-Blind Randomized Clinical Trial[J]. J Obstet Gynaecol Can, 2022, 44(4):383-389. doi: 10.1016/j.jogc.2021.11.010. doi: 10.1016/j.jogc.2021.11.010 URL
[39]	Pourmoghadam Z, Soltani-Zangbar MS, Sheikhansari G, et al. Intrauterine administration of autologous hCG- activated peripheral blood mononuclear cells improves pregnancy outcomes in patients with recurrent implantation failure; A double-blind, randomized control trial study[J]. J Reprod Immunol, 2020, 142:103182. doi: 10.1016/j.jri.2020.103182. doi: 10.1016/j.jri.2020.103182 URL